| Literature DB >> 26542731 |
Roberta Ferrucci1,2, Francesca Cortese1, Marta Bianchi3, Dario Pittera1, Rosanna Turrone3, Tommaso Bocci1,4, Barbara Borroni3, Maurizio Vergari1, Filippo Cogiamanian1, Gianluca Ardolino1, Alessio Di Fonzo1, Alessandro Padovani3, Alberto Priori5,6,7.
Abstract
Transcranial direct current stimulation (tDCS) is a non-invasive technique for inducing prolonged functional changes in the human cerebral cortex. This simple and safe neurostimulation technique for modulating motor functions in Parkinson's disease could extend treatment option for patients with movement disorders. We assessed whether tDCS applied daily over the cerebellum (cerebellar tDCS) and motor cortex (M1-tDCS) improves motor and cognitive symptoms and levodopa-induced dyskinesias in patients with Parkinson's disease (PD). Nine patients (aged 60-85 years; four women; Hoehn & Yahr scale score 2-3) diagnosed as having idiopathic PD were recruited. To evaluate how tDCS (cerebellar tDCS or M1-tDCS) affects motor and cognitive function in PD, we delivered bilateral anodal (2 mA, 20 min, five consecutive days) and sham tDCS, in random order, in three separate experimental sessions held at least 1 month apart. In each session, as outcome variables, patients underwent the Unified Parkinson's Disease Rating Scale (UPDRS III and IV) and cognitive testing before treatment (baseline), when treatment ended on day 5 (T1), 1 week later (T2), and then 4 weeks later (T3), at the same time each day. After patients received anodal cerebellar tDCS and M1-tDCS for five days, the UPDRS IV (dyskinesias section) improved (p < 0.001). Conversely, sham tDCS, cerebellar tDCS, and M1-tDCS left the other variables studied unchanged (p > 0.05). Despite the small sample size, our preliminary results show that anodal tDCS applied for five consecutive days over the motor cortical areas and cerebellum improves parkinsonian patients' levodopa-induced dyskinesias.Entities:
Keywords: Cerebellar tDCS; Cerebellum; Levodopa-induced dyskinesias; Parkinson; tDCS
Mesh:
Substances:
Year: 2016 PMID: 26542731 DOI: 10.1007/s12311-015-0737-x
Source DB: PubMed Journal: Cerebellum ISSN: 1473-4222 Impact factor: 3.847